Thompson Investment Management Inc. Sells 425 Shares of Cambrex Co. (NYSE:CBM)

Thompson Investment Management Inc. cut its holdings in Cambrex Co. (NYSE:CBM) by 3.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,150 shares of the biotechnology company’s stock after selling 425 shares during the period. Thompson Investment Management Inc.’s holdings in Cambrex were worth $782,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Yorktown Management & Research Co Inc bought a new position in Cambrex in the 3rd quarter worth approximately $250,000. Gabelli Funds LLC bought a new position in Cambrex in the 3rd quarter valued at $14,458,000. Gamco Investors INC. ET AL bought a new position in Cambrex in the 3rd quarter valued at $658,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in Cambrex in the 3rd quarter valued at $9,259,000. Finally, Russell Investments Group Ltd. boosted its holdings in Cambrex by 43.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 85,303 shares of the biotechnology company’s stock valued at $5,076,000 after purchasing an additional 25,845 shares during the period.

Shares of Cambrex stock traded up $0.03 on Friday, hitting $59.82. 155,870 shares of the company traded hands, compared to its average volume of 433,362. The firm’s 50-day simple moving average is $59.65 and its 200 day simple moving average is $50.95. The company has a current ratio of 2.37, a quick ratio of 1.70 and a debt-to-equity ratio of 0.76. The company has a market cap of $2.02 billion, a P/E ratio of 21.60, a P/E/G ratio of 4.67 and a beta of 2.17. Cambrex Co. has a 12-month low of $33.80 and a 12-month high of $60.29.

Several research analysts have commented on the stock. Zacks Investment Research downgraded shares of Cambrex from a “buy” rating to a “hold” rating in a report on Tuesday, October 29th. Craig Hallum downgraded shares of Cambrex from a “buy” rating to a “hold” rating and set a $60.00 price target for the company. in a report on Monday, August 12th. ValuEngine downgraded shares of Cambrex from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 9th. Finally, William Blair downgraded shares of Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 price target for the company. in a report on Wednesday, August 7th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $54.83.

About Cambrex

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Featured Story: Momentum Investing

Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.